Cargando…
Funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors
The time from identifying a drug target to a new drug approval is often measured in decades and can take even longer for therapies to treat rare diseases. In fact, 95% of rare diseases do not have a specific therapy approved at all. Coordinated efforts to augment the drug development pipeline along...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949486/ https://www.ncbi.nlm.nih.gov/pubmed/31793149 http://dx.doi.org/10.15252/emmm.201911656 |